Mirum Pharmaceuticals Reported Positive Hepatitis B Trial
The experimental monoclonal antibody brelovitug successfully reduced virus levels in a late-stage clinical study.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Are pharmaceutical companies making enough progress in developing new treatments for chronic viral infections?
Mirum Pharmaceuticals announced that its experimental monoclonal antibody, brelovitug, met its primary endpoint in a late-stage study. The therapy aims to lower virus levels in patients suffering from hepatitis B.
Why it matters
This research-stage development targets the hepatitis B surface antigen protein, representing a potential new pathway for managing chronic viral infection.
The experimental monoclonal antibody — a laboratory-made molecule that mimics immune system antibodies — functions by targeting the hepatitis B surface antigen protein. The study reached its primary efficacy goal, though specific viral load reduction percentages were not disclosed.
The players
Mirum Pharmaceuticals
A biopharmaceutical company focused on developing therapies for rare diseases and complex viral conditions.
The details
Brelovitug works by binding to the surface antigen protein of the hepatitis B virus to reduce viral presence in the body. This approach leverages the specificity of monoclonal antibodies to interfere with the virus's ability to persist in the host, though the study remains in the research-stage of clinical development.
Timeline
September 28, 2026: Mirum Pharmaceuticals released the late-stage study results on Monday.
The Tech Race
The study contributes to the competitive landscape of antiviral development by testing a targeted monoclonal approach against standard chronic management protocols. It builds upon current research efforts to reduce surface antigen levels in patients who have not achieved full viral suppression.
As this drug is currently in a research-stage clinical trial, it is not available for patient use or prescription. Its eventual path to the clinic depends on further regulatory review and the completion of additional safety and efficacy milestones.
The takeaway
The success of this trial marks a key step in evaluating monoclonal antibodies for hepatitis B management. Interested parties should watch for the upcoming publication of the full data set and subsequent presentations at medical conferences.
Further reading
Learn more about the latest research in this field at the Biotech section.
Source note: This article includes information reported by ARY News.
Live Poll
Are pharmaceutical companies making enough progress in developing new treatments for chronic viral infections?
